Gevokizumab is a potent anti-IL-1beta antibody, negatively modulates IL-1beta signaling through an allosteric mechanism. Gevokizumab selectively decreases the binding affinity of IL-1beta for the IL-1 receptor type I (IL-1RI) signaling receptor instead of IL-1 counter-regulatory decoy receptor (IL-1 receptor type II)[1][2].
Molecular Weight:
(145.12 kDa)
Purity:
98.12
CAS Number:
[1129435-60-4]
Target:
Interleukin Related
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted